Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Van Oorschot, Desirée, Anastassopoulou, Anastassia, Poulsen Nautrup, Barbara, Varghese, Lijoy, von Krempelhuber, Alfred, Neine, Mohamed, Lorenc, Stéphane, Curran, Desmond
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363061/
https://ncbi.nlm.nih.gov/pubmed/30130448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1509645
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia